Skip to main content

Design Therapeutics, Inc. (DSGN)

NASDAQ: DSGN · Delayed Price · USD
16.17 0.19 (1.19%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap891.20M
Revenue (ttm)53,000
Net Income (ttm)n/a
Shares Out55.08M
EPS (ttm)-0.91
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume135,189
Open15.95
Previous Close15.98
Day's Range15.35 - 17.03
52-Week Range13.93 - 50.50
Betan/a
AnalystsBuy
Price Target34.67 (+114.4%)
Est. Earnings DateNov 8, 2021

About DSGN

Design Therapeutics is a preclinical-stage biopharmaceutical company pioneering novel small-molecule therapeutic candidates, called gene targeted chimeras (GeneTACs), that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases, of which there are more than 40 debilitating degenerative diseases. Individuals with nucleotide repeat expansion diseases are born with abnormally expanded stretches of specific nucleotide sequences, often with hundreds to thousands of excess repeats present...

IndustryBiotechnology
IPO DateMar 26, 2021
CEOJou00e3o Siffert, M.D.
Employees25
Stock ExchangeNASDAQ
Ticker SymbolDSGN
Full Company Profile

Financial Performance

In 2020, DSGN's revenue was $226,000, a decrease of -72.90% compared to the previous year's $834,000. Losses were -$8.28 million, 304.5% more than in 2019.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for DSGN stock is "Buy." The 12-month stock price forecast is 34.67, which is an increase of 114.41% from the latest price.

Price Target
$34.67
(114.41% upside)
Analyst Consensus: Buy

News

Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 Gen...

Data to be Presented during the 2021 Virtual Myotonic Dystrophy Foundation Annual Conference Data to be Presented during the 2021 Virtual Myotonic Dystrophy Foundation Annual Conference

1 week ago - GlobeNewsWire

4 Stocks Insiders Are Buying

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.

Other symbols:EVERPCGSXT
2 weeks ago - Benzinga

Design Therapeutics Reports GeneTAC™ Portfolio Progress and Second Quarter 2021 Results

Preclinical Data Support Initiation of Clinical Development of Lead GeneTAC Program for Friedreich Ataxia in the First Half of 2022

1 month ago - GlobeNewsWire

Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that João S...

3 months ago - GlobeNewsWire

Design Therapeutics Expands Board of Directors with Key Appointments

CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced the appoin...

3 months ago - GlobeNewsWire

Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results

Successful $276 Million IPO Completed to Advance GeneTAC TM Programs for Friedreich Ataxia and Myotonic Dystrophy Type-1 Toward Clinical Development

4 months ago - GlobeNewsWire

Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchas...

CARLSBAD, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN) (“Design”), a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecule...

5 months ago - GlobeNewsWire

Design Therapeutics Announces Pricing of Initial Public Offering

CARLSBAD, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc., a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of ser...

5 months ago - GlobeNewsWire

Preclinical autoimmune disease biotech Design Therapeutics files for a $100 million IPO

Design Therapeutics, a preclinical biotech developing gene targeted chimeras for nucleotide expansion diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

6 months ago - NASDAQ

Design Therapeutics IPO Registration Document (S-1)

Design Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

6 months ago - SEC